Section Arrow
VTVT.NASDAQ
- vTv Therapeutics
Quotes are at least 15-min delayed:2026/01/08 06:17 EST
Pre Market
Last
 --
-- (--)
Bid
25.38
Ask
45.14
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 41.99
-0.725 (-1.70%)
Day High 
43.07 
Prev. Close
42.715 
1-M High
44 
Volume 
39.89K 
Bid
25.38
Ask
45.14
Day Low
39.98 
Open
43.0423 
1-M Low
28.0783 
Market Cap 
168.21M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 39.07 
20-SMA 36.53 
50-SMA 30.52 
52-W High 41.49 
52-W Low 13.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.30/-4.01
Enterprise Value
168.21M
Balance Sheet
Book Value Per Share
17.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.02M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
Pre Market 0.1215 -0.0041 -3.26%
ERASErasca5.17+1.54+42.42%-- 
Pre Market 4.52 -0.65 -12.57%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
Pre Market 4.77 -0.09 -1.85%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
Pre Market 13.74 +0.01 +0.07%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
Pre Market 22.99 -0.29 -1.25%
Industry overview quotes are at least 15 minutes delayed
Business Description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.